Comparative Pharmacology
Head-to-head clinical analysis: FLAVALTA versus FLAVOXATE HYDROCHLORIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FLAVALTA versus FLAVOXATE HYDROCHLORIDE.
FLAVALTA vs FLAVOXATE HYDROCHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Flavoxate is a smooth muscle relaxant with anticholinergic and local anesthetic properties. It inhibits phosphodiesterase, leading to increased cAMP levels, which reduces smooth muscle tone in the urinary tract.
Flavoxate hydrochloride is a smooth muscle relaxant with anticholinergic and local anesthetic properties. Its mechanism of action involves direct inhibition of smooth muscle contraction in the urinary tract, reducing detrusor muscle spasm, and decreasing urinary frequency and urgency.
FLAVALTA is not a recognized drug. No data available.
100-200 mg orally 3-4 times daily; maximum 800 mg/day.
None Documented
None Documented
Terminal elimination half-life is 6.5 hours (range 5.0-8.0 hours), allowing twice-daily dosing in most patients.
Approximately 3-4 hours; clinical context: short half-life supports multiple daily dosing in overactive bladder therapy.
Primarily hepatic metabolism followed by biliary excretion (60-70% as metabolites), renal excretion (20-30% unchanged drug and metabolites), and fecal elimination (5-10%).
Renal: approximately 30-60% of an oral dose is excreted unchanged in urine; the remainder is metabolized and eliminated via bile and feces.
Category C
Category C
Urinary Antispasmodic
Urinary Antispasmodic